Our Capital Markets team advised the investment bank Stifel on €10 million fundraising of Adocia, carried out through a private placement via the issuance of new ordinary shares, each with one share warrant attached (ABSA).
The fundraising will be used primarily to support the continued development of Adocia’s proprietary technology platforms, in particular to finance the development of the AdoXLong platform, the industrialization of the BioChaperone technology, and the Company’s working capital requirements.
Adocia is a biotechnology company listed on Euronext Paris, specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Goodwin team was led by Guilhem Richard and Shanna Kim on the French law aspects, as well as Edwin O’Connor on the U.S. law aspects.